Overall, the 5‐year outcomes of the KEYNOTE‐024 study indicated that pembrolizumab, as the first‐line treatment of advanced NSCLC with a PD‐L1 TPS ≥50%, provides a clinically meaningful long‐term OS benefits versus platinum‐based chemotherapy. The gene discussed is CD274; the disease is non-small cell lung carcinoma.